Menu

 

ENGOT-ov11/MILO

 

This multinational, 2:1 randomized, open-label Phase 3 study will evaluate MEK162 vs. physician’s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan) in patients with LGS
carcinomas of the ovary, fallopian tube or primary peritoneum who have recurrent or persistent disease following at least 1 prior platinum-based chemotherapy treatment and no more than 3 prior lines of
chemotherapy. This study evaluates whether MEK162 will prolong PFS compared to psysician’s choice of chemotherapy. A total of approximately 300 matients are planned. 


 

Symptom Benefit      

Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer? Measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum resistant or refractory ovarian cancer.

The purpose of this study is to develop a measure of symptom benefit that can be used as an endpoint in clinical trials of palliative chemotherapy.

 


 

NSGO-CC-0304 – Combretastatin

Phase I-II-III studies of Cisplatin and Combretastatin (CA4P) in recurrent or advanced Cervical Cancer.

Link to protocol


NSGO-CC-0301

A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma. A non-randomized, open, multi-centre, phase II study to evaluate the effect of radiotherapy and concomitant cisplatin in patients with locally advanced or relapsed vulvar cancer.

Link to protocol

 


NSGO-CC-9901 – Concurrent NOCECA

A feasibility study of Concurrent Treatment with Cisplatin and Radiotherapy for cancer of the uterine Cervix stage IIB- IV A.

Link to protocol


 

NOCECA 93

Protocol for the Treatment of Cervix Cancer Stage IIb-IVa.

Link to protocol


NSGO-EC-0302 Exemestan

Endometrial Carcinoma. A Phase II study. This is a non-randomized, multi-centre, phase II study to evaluate the efficacy of Exemestane in patients with histopatholgical/ cytological proven advanced or recurrent endometrial carcinoma

Link to protocol


Molecular Markers in Treatment in Endometrial Cancer (MoMaTEC)

The purpose of this prospective multicenter trial is to investigate the value of molecular markers in endometrial cancer for predicting lymph node metastasis and prognosis in relation to treatment.

Link to trial description on clinicaltrials.gov


NSGO-EC-9501 High‑risk Endometrial Carcinoma

A randomized trial of adjuvant treatment with radiation plus chemotherapy versus radiation alone in high-risk endometrial carcinoma. Multinational, open, randomized Phase III study. The purpose of this study is to evaluate the efficacy of the addition of adjuvant chemotherapy to the traditional treatment with pelvic radiation in patients with an early endometrial primary cancer with histopathologic risk factors but without postoperative macroscopic residual tumor.

Link to protocol synopsis


CALYPSO

Multi-national, randomized, phase III, GCIG Intergroup study comparing pegylated liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in patients with epithelial ovarian cancer in late relapse.

Link to trial description on clinicaltrials.gov


NSGO-OC-0303 – Carbo-Taxotere

A phase II study of docetaxel + carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or tubal cancer.

 

 


NSGO-OC-0101 – OVA-Resist

A randomized study of chemotherapy versus hormonal treatment in patients with ovarian cancer resistant or refractory to platinum and taxane. Primary endpoint: Evaluation of quality of life for patients treated with either of the two regimes. Secondary endpoint: Evaluation of progression free and overall survival.

Link to the protocol


OVAR9

Carboplatin and Paclitaxel With or Without Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer. This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.

Link to trial description on clinicaltrials.gov


NSGO-OC-9804 – TEC vs TC
 
Paclitaxel/Epirubicin/Carboplatin combination (TEC) versus Paclitaxel/Carboplatin (TC) in treatment of women with advanced Ovarian cancer.

 

mEOC

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer (mEOC/GOG-0241)

This randomized phase III trial is studying carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II, stage III, stage IV, or recurrent stage I epithelial ovarian cancer or fallopian tube cancer.
 

ICON 7

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer.
This randomized phase III trial is studying carboplatin, paclitaxel, and bevacizumab to see how well they work compared with carboplatin and paclitaxel alone in treating patients with newly diagnosed ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cavity cancer.

Link to trial description on clinicaltrials.gov